Core Viewpoint - Hendi Pharmaceutical (301211.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges for the company [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 235 million yuan, a year-on-year decrease of 2.93% [1] - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 4.42 million yuan, a decline of 93.21% year-on-year [1] - The net cash flow from operating activities was 8.40 million yuan, down 73.71% year-on-year [1] - In 2024, the company reported operating revenue of 446 million yuan, a decrease of 32.75% year-on-year [1] - The net profit attributable to shareholders for 2024 was 91.55 million yuan, down 48.02% year-on-year [1] - The net profit after deducting non-recurring gains and losses for 2024 was 72.95 million yuan, a decline of 57.14% year-on-year [1] - The net cash flow from operating activities for 2024 was 96.07 million yuan, down 29.91% year-on-year [1] IPO and Fundraising - The total amount raised from the initial public offering (IPO) was 1.548 billion yuan, with a net amount of 1.401 billion yuan, exceeding the original target by 210 million yuan [2] - The company initially planned to raise 1.19 billion yuan for various projects, including the production of ibuprofen and other active pharmaceutical ingredients [2] - The IPO expenses amounted to 147 million yuan, with underwriting fees of 132 million yuan [2] Stock Actions - On May 24, 2023, the company announced a stock bonus plan of 2 shares for every 10 shares held, along with a pre-tax dividend of 4 yuan [3] - On August 1, 2025, the company announced a new stock bonus plan of 4.5 shares for every 10 shares held [4]

Financial Performance Summary - The company reported total revenue of 235 million yuan for the first half of 2025, a decrease of 2.93% year-on-year [1] - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% compared to the previous year [1] - The gross profit margin was 21.9%, reflecting a significant decline of 39.16% year-on-year [1] - The net profit margin decreased to 7.9%, down 72.1% from the previous year [1] - The total of selling, administrative, and financial expenses amounted to 26.98 million yuan, accounting for 11.49% of revenue, an increase of 334.54% [1] Key Financial Metrics - Revenue for 2024 was 242 million yuan, compared to 235 million yuan in 2025 [1] - The net profit for 2024 was 68.50 million yuan, while it dropped to 18.55 million yuan in 2025 [1] - The cash and cash equivalents decreased by 47.18% to 540 million yuan [1] - The company's earnings per share fell to 0.06 yuan, a decrease of 75% year-on-year [1] Expense Analysis - Selling expenses increased by 13.2% due to heightened sales efforts [2] - Financial expenses surged by 85.51% primarily due to reduced interest income [3] - Research and development expenses decreased by 17.72% as fewer projects were initiated compared to the previous period [4] Cash Flow Insights - Net cash flow from operating activities decreased by 73.71% due to reduced interest income [4] - Net cash flow from investing activities increased by 109.22% as fewer large certificates of deposit were purchased [4] - Net cash flow from financing activities rose by 47.33% due to a reduction in dividend distribution compared to the previous year [4] Company Strategy and Future Plans - The company currently has no plans for share buybacks, but will disclose any future plans in accordance with regulations [5]

Core Viewpoint - Hendi Pharmaceutical (301211) reported significant declines in revenue and profit for the first half of 2025, indicating substantial operational pressure and a need for cost optimization to restore profitability [2][6]. Financial Performance Overview - Total revenue for Hendi Pharmaceutical was 235 million yuan, a year-on-year decrease of 2.93% - Net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year - Non-recurring net profit was 4.42 million yuan, a decline of 93.21% year-on-year - In Q2, total revenue was 120 million yuan, an increase of 15.91% year-on-year, but net profit was 8.22 million yuan, down 73.58% year-on-year [2]. Profitability Analysis - The company's gross margin was 21.9%, a decrease of 39.16% year-on-year - Net margin was 7.9%, down 72.1% year-on-year - Earnings per share were 0.06 yuan, a reduction of 75.0% year-on-year, indicating a significant drop in overall profitability despite revenue recovery in Q2 [3]. Expense Control and Cash Flow - The ratio of operating expenses (selling, administrative, and financial expenses) to total revenue was 11.49%, an increase of 334.54% year-on-year - Selling expenses increased by 13.2%, while financial expenses rose by 85.51% - Net cash flow from operating activities was 0.03 yuan per share, a decrease of 73.71% year-on-year, primarily due to reduced interest income [4]. Main Business Composition - Revenue from non-steroidal anti-inflammatory products was 160 million yuan, accounting for 68.06% of total revenue, with a gross margin of 15.27% - Cardiovascular products generated 37.76 million yuan, representing 16.08% of total revenue, with a high gross margin of 71.83% - Other products contributed 20.81 million yuan (8.86% of total revenue) with a gross margin of 8.44% - Antitumor products generated 16.42 million yuan (6.99% of total revenue) with a negative gross margin of -11.32% [5]. Development Review and Outlook - R&D investment was approximately 15.88 million yuan, down 17.72% year-on-year - The company obtained drug registration certificates for several products and made progress on multiple projects - A subsidiary passed FDA cGMP inspections, and the company was re-certified as a high-tech enterprise - Overall, Hendi Pharmaceutical faces significant operational challenges in H1 2025, with a notable decline in performance and rising expenses impacting profitability [6].

Core Viewpoint - Hendy Pharmaceutical (301211) reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 was 235 million yuan, a decrease of 2.93% year-on-year [1]. - Net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1]. - Gross margin fell to 21.9%, a decline of 39.16% compared to the previous year [1]. - Net margin decreased to 7.9%, down 72.1% year-on-year [1]. - The total of selling, administrative, and financial expenses reached 26.98 million yuan, accounting for 11.49% of total revenue, an increase of 334.54% year-on-year [1]. Cash Flow and Expenses - Operating cash flow per share was 0.03 yuan, a decrease of 73.71% year-on-year [1]. - The company experienced a significant increase in financial expenses, which rose by 85.51% due to reduced interest income [3]. - The net cash flow from operating activities decreased by 73.71%, attributed to lower interest income [3]. Investment and Return Metrics - The company's return on invested capital (ROIC) was 1.92%, indicating weak capital returns [4]. - Historical data shows a median ROIC of 10.31% since the company went public, suggesting better investment returns in previous years [4]. Company Strategy and Future Plans - The company currently has no plans for share buybacks, but will disclose any future plans in accordance with regulations [5][6].

Core Viewpoint - Hendi Pharmaceutical (301211) reported that as of July 31, 2025, the number of shareholders is 18,153 [1] Company Summary - Hendi Pharmaceutical has engaged with investors through an interactive platform, providing updates on shareholder numbers [1]

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计，8月1日共有9家公司公布2025年半年报，其中3家净利润同比增长，6家同比下 降，4家营业收入同比增长，5家同比下降，净利润和营业收入同时增长的公司有道道全等3家，净利润 和营业收入均下降的有翔丰华等5家，业绩增幅翻倍的公司有2家，其中道道全增幅最大，达563.15%。 （数据宝） 今日公布半年报公司一览 | 代码 | 简称 | 每股收益 | 净利润（万 | 净利润同比 | 营业收入（万 | 营业收入同比 | | --- | --- | --- | --- | --- | --- | --- | | | | （元） | 元） | （%） | 元） | （%） | | 002852 | 道道全 | 0.5300 | 18097.60 | 563.15 | 279243.96 | 1.16 | | 300641 | 正丹股 份 | 1.2000 | 63000.60 | 120.35 | 142874.46 | 3.37 | | 838262 | 太湖雪 | 0.2824 | 1898.49 | 69.7 ...

公司营业总收入为2.35亿元。归母净利润为1854.71万元。经营活动现金净流入为840.13万元。 公司股东户数为1.71万户，前十大股东持股数量为2.19亿股，占总股本比例为75.94%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 上海勇达圣商务咨询有限公司 | 38.2. | | 2 | 刘天超 | 12.00 | | 3 | 荆门市宁康企业管理中心(有限合伙) | 5.63 | | 4 | 刘妍超 | 4.50 | | 5 | 刘雯超 | 4.50 | | 6 | 刘思超 | 4.50 | | 7 | 雷小艳 | 3.75 | | 8 | 荆门市倍康企业管理中心(有限合伙) | 1.88 | | g | 香港中央结算有限公司 | 0.59 | | 10 | 李雪红 | 0.35 | 公司摊薄每股收益为0.06元。 2025年8月1日，亨迪药业(301211.SZ)发布2025年中报。 公司最新总资产周转率为0.10次。最新存货周转率为1.45次，较去年同期存货周转率增加0.57次，同比较去年同期上涨65.23%。 公司最新资产负债 ...

所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 证券代码：301211 证券简称：亨迪药业 公告编号：2025-031 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 √是 □否 公司经本次董事会审议通过的利润分配预案为：以288000000为基数，向全体股东每10股派发现金红利0 元（含税），送红股0股（含税），以资本公积金向全体股东每10股转增4.5股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 □适用 √不适用 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 公 ...

Group 1 - The company has approved a profit distribution plan, distributing 0 cash dividends and 0 bonus shares per 10 shares, while increasing capital reserves by 4.5 shares per 10 shares to all shareholders [2] - There has been no retrospective adjustment or restatement of previous accounting data [2] - The company has not experienced any changes in its controlling shareholder during the reporting period [3] Group 2 - The actual controller of the company has not changed during the reporting period [4] - There are no preferred shareholders or related holdings reported during the period [4] - There are no outstanding bonds as of the date of the semi-annual report approval [4]

湖北亨迪药业股份有限公司 2025 年半年度报告全文 湖北亨迪药业股份有限公司 湖北亨迪药业股份有限公司 2025 年半年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人程志刚、主管会计工作负责人易廷浩及会计机构负责人(会计 主管人员)全纯华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请 投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 288000000 为基数， 向全体股东每 10 股派发现金红利 0 元（含税），送红股 0 股（含税），以资 本公积金向全体股东每 10 股转增 4.5 股。 限公司 2025 年半年度报告全文 湖北亨迪药业股份有限公司 2025 年半年度报告全文 | | 释义 | | | --- | --- | --- | | 释义项 | 指 | 释义内容 ...